Guangzhou Wondfo Biotech Co.,Ltd
SZSE:300482 Stok Raporu
Guangzhou Wondfo BiotechLtd Gelecekteki Büyüme
Future kriter kontrolleri 5/6 Guangzhou Wondfo BiotechLtd kazanç ve gelirin sırasıyla yıllık 27.5% ve 21.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 26.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.9% olacağı tahmin edilmektedir.
Anahtar bilgiler Medical Equipment kazanç büyümesi 27.0% Gelir büyüme oranı 21.1% Gelecekteki özkaynak getirisi 13.9% Analist kapsamı Low
Son güncelleme 29 Oct 2024
Gelecekteki son büyüme güncellemeleri
Price target decreased by 7.6% to CN¥33.55 Jul 09
Price target decreased to CN¥60.42 Nov 22
Consensus revenue estimates increase by 34% May 01
Price target decreased to CN¥68.96 Sep 14
Tüm güncellemeleri göster
High number of new directors Nov 05
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit Nov 01
Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 3Q 2023) Oct 25
New minor risk - Share price stability Sep 30
Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024 Sep 30
Investor sentiment improves as stock rises 18% Sep 27
Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely Sep 06
Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.30 in 2Q 2023) Aug 14
Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture Jul 27
Price target decreased by 7.6% to CN¥33.55 Jul 09
Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 14, 2024 Jun 29
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations Apr 29
Investor sentiment improves as stock rises 20% Apr 24
First quarter 2024 earnings released: EPS: CN¥0.49 (vs CN¥0.46 in 1Q 2023) Apr 22
New minor risk - Shareholder dilution Apr 08
Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 22, 2024 Mar 30
A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price Mar 27
There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital Feb 29
Investor sentiment deteriorates as stock falls 15% Feb 02
Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 22, 2024 Dec 29
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Oct 26
Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.62 in 2Q 2022) Aug 16
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares. Jul 07
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 01
Now 20% undervalued after recent price drop Feb 13
Now 20% undervalued Dec 20
Investor sentiment deteriorated over the past week Dec 19
Investor sentiment improved over the past week Nov 30
Now 23% undervalued Nov 23
Price target decreased to CN¥60.42 Nov 22
Insufficient new directors Nov 16
Investor sentiment improved over the past week Nov 04
Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.16 in 3Q 2021) Oct 28
Investor sentiment improved over the past week Oct 18
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares. Sep 27
Second quarter 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.90 in 2Q 2021) Aug 26 Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding Aug 20
Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022 Jun 09
Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2021 May 24
Consensus revenue estimates increase by 34% May 01
Less than half of directors are independent Apr 27
Guangzhou Wondfo Biotech Co.,Ltd. Announces Profit Distribution Proposal for 2021 Apr 26
Investor sentiment improved over the past week Apr 15
Investor sentiment improved over the past week Mar 14
Investor sentiment improved over the past week Feb 28
Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.27 in 3Q 2020) Oct 26
Price target decreased to CN¥68.96 Sep 14
Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 80 million worth of its shares. Sep 08
Second quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.79 in 2Q 2020) Aug 26
Investor sentiment deteriorated over the past week Aug 20
Investor sentiment improved over the past week Aug 03
Guangzhou Wondfo Biotech Co.,Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 26 May 2021 May 21
First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.29 in 1Q 2020) Apr 30
Investor sentiment improved over the past week Apr 26
Full year 2020 earnings released: EPS CN¥1.87 (vs CN¥1.14 in FY 2019) Apr 01
Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021 Feb 24
Wondfo Rams Up Neutralizing Antibody, Antigen and PCR Tests to Address the Evolving Demands for COVID-19 Testing Globally Feb 02
New 90-day high: CN¥95.02 Jan 22
New 90-day high: CN¥90.79 Dec 25
Investor sentiment improved over the past week Dec 25
New 90-day low: CN¥74.05 Nov 06
Third quarter earnings released Oct 30
New 90-day low: CN¥81.99 Oct 22
New 90-day low: CN¥83.05 Sep 30
New 90-day low - CN¥84.82 Sep 10
First half earnings released Aug 29
Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2020 Results on Aug 28, 2020 Aug 13
Kazanç ve Gelir Büyüme Tahminleri SZSE:300482 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions ) Tarih Gelir Kazançlar Serbest Nakit Akışı Faaliyetlerden Nakit Avg. Analist Sayısı 12/31/2026 4,775 1,013 N/A 1,086 4 12/31/2025 3,951 818 N/A 917 4 12/31/2024 3,265 649 N/A 927 4 9/30/2024 2,942 524 107 538 N/A 6/30/2024 2,852 509 230 624 N/A 3/31/2024 2,794 502 289 664 N/A 12/31/2023 2,765 488 -104 329 N/A 9/30/2023 2,989 357 116 569 N/A 6/30/2023 3,136 354 -56 459 N/A 3/31/2023 3,887 497 1,268 1,818 N/A 1/1/2023 5,681 1,197 1,099 1,682 N/A 9/30/2022 5,550 1,247 905 1,472 N/A 6/30/2022 5,538 1,257 898 1,461 N/A 3/31/2022 5,290 1,383 -270 287 N/A 12/31/2021 3,361 634 208 665 N/A 9/30/2021 3,145 695 18 621 N/A 6/30/2021 3,060 741 -1 557 N/A 3/31/2021 2,956 692 113 594 N/A 12/31/2020 2,811 634 642 1,062 N/A 9/30/2020 2,821 663 657 886 N/A 6/30/2020 2,711 630 885 1,053 N/A 3/31/2020 2,172 413 595 775 N/A 12/31/2019 2,072 387 131 310 N/A 9/30/2019 1,921 375 175 329 N/A 6/30/2019 1,817 352 137 296 N/A 3/31/2019 1,748 325 97 232 N/A 12/31/2018 1,650 308 117 248 N/A 9/30/2018 1,542 280 69 198 N/A 6/30/2018 1,498 264 N/A 175 N/A 3/31/2018 1,323 231 N/A 186 N/A 12/31/2017 1,145 211 N/A 169 N/A 9/30/2017 921 181 N/A 51 N/A 6/30/2017 747 174 N/A 100 N/A 3/31/2017 624 154 N/A 116 N/A 12/31/2016 547 145 N/A 112 N/A 9/30/2016 525 158 N/A 143 N/A 6/30/2016 486 147 N/A 141 N/A 3/31/2016 450 131 N/A 145 N/A 12/31/2015 429 125 N/A 132 N/A 9/30/2015 382 106 N/A 108 N/A 6/30/2015 380 105 N/A 99 N/A 3/31/2015 365 96 N/A 107 N/A 12/31/2014 365 98 N/A 104 N/A 12/31/2013 248 59 N/A 101 N/A
Daha fazla göster
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 300482 'nin tahmini kazanç büyümesi (yıllık 27.5% ) tasarruf oranının ( 2.8% ) üzerindedir.
Kazançlar ve Piyasa: 300482 şirketinin kazançlarının (yıllık 27.5% ) CN pazarından (yıllık 26.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: 300482 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: 300482 şirketinin gelirinin (yıllık 21.1% ) CN pazarından (yıllık 14.1% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: 300482 şirketinin gelirinin (yıllık 21.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 300482 'nin Özsermaye Getirisi 'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.9 %).
Büyüyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}